StockWatch
·

Tega Industries Ltd Q2 FY27 Results

TEGAQ2 FY27 Results
Filing
Result:Poor· Market: Down#One-off hit#Margin squeeze

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue4.3K146.8%949.5%
Total Income4.3K146.7%919.9%
Expenditure4.2K127.4%1058.4%
PBT69.35159.1%23.1%
Net Profit-58.7745.7%230.8%
OPM11.50%8.28pp5.57pp
NPM-1.37%4.85pp12.04pp
EPS-6.32155.1%193.6%
View full financials

Industrials core metric (adjusted PAT) fell ~83% YoY with a swing from profit to a reported loss, margins compressed to ~13.1% (below guidance and down from 17.1%), and finance costs on acquisition debt already overshot full-year guidance within H1 — a clear deterioration, not a one-off-driven blip.

TEGA INDUSTRIES · Q2 FY-2027 · THE VERDICT

Molycop Masks the Real Issue: Equipment Missed, Finance Costs Stay Elevated

Reported loss of ₹1,670 Cr obscures an adjusted profit of ₹452 Cr and a functioning acquisition. The real story is that equipment guidance was cut 25% to 15% and finance costs remain ₹4,086 Cr in H1—10 times prior guidance. That's the problem management hasn't solved.

12 Nov 2026 · 6 min read
Reported PAT

-₹1,670 Cr

includes ₹2,576 Cr acquisition costs

Adjusted PAT

₹452 Cr

10.6% margin (organic)

Consolidated EBITDA margin

14.2%

-80 bps vs 15% target

Molycop EBITDA margin (3m)

14.7%

first quarter post-acquisition

The gap: reported vs. adjusted

Tega's Q2 loss of ₹1,670 Cr is almost entirely one-time: ₹2,576 Cr in acquisition costs, ₹117 Cr in inventory step-up, and ₹1,235 Cr in tax charges related to the Molycop consolidation. Strip these, and adjusted PAT is ₹452 Cr on ₹4,254 Cr revenue—a 10.6% margin. That's the organic number. But Molycop itself is only three months into consolidation and delivered 14.7% EBITDA on ₹3,771.6 Cr revenue. The company is functioning; the math is obscured.

What the call claims, and what holds up

Management's on-call claims vs. actual delivery

Molycop delivered 14% EBITDA margin in first quarter

Supported

Three-month adjusted EBITDA ₹554 Cr on ₹3,771.6 Cr = 14.7% margin

Equipment business +72% QoQ growth in Q2

Contradicted

Sequential recovery from weak Q1 base; YoY down 5%. Guidance cut from 25% to 15% due to customer order delays.

Consumables grew 20% YoY in H1

Supported

H1 consumables ₹9,143 Cr vs ₹7,614 Cr prior = +20.1% YoY

Finance costs will normalize after non-core monetization in 12–18 months

Overstated

H1 finance cost ₹4,086 Cr vs prior ₹110–120 Cr FY27 guidance (~₹27.5 Cr quarterly). No committed timeline for relief.

What changed on this call

  • Equipment guidance cut 25% → 15%. Explicit mid-year revision. Customers have pushed orders to next quarter; management expects 'strong rebound' H2 but no quantified timeline.

  • Molycop added June 1; delivered 14.7% EBITDA in first three months. Within legacy guidance zone (~15%). Integration mechanics on track: 500-ton grinding media trial secured with existing Tega mill-liner customer.

  • Finance cost guidance completely missed. Prior: ₹110–120 Cr FY27 annual. Actual: ₹4,086 Cr H1 (₹2,043 Cr per quarter). Includes ₹500 Cr preference dividend and Molycop acquisition debt. Monetization timeline vague.

  • Grasberg mine recovery at 67% of normal throughput. Contingent upside if recovery accelerates toward 80% by mid-2027. Cobre Panamá contingent payments hinge on mining permit restoration.

The bull-bear ledger

  • Molycop at 14.7% EBITDA delivered on first quarter; within long-term target zone

  • Consumables +20% YoY beats long-term 15% CAGR guidance; margin expansion to 22.4%

  • Order book ₹13,976 Cr (+14% QoQ) provides H2 revenue visibility

  • Equipment guidance cut signals softness; only +2% QoQ, -5% YoY despite healthy order book

  • Finance costs ₹4,086 Cr H1 (10× prior guidance); adjusted PAT margin 10.6% lags reported EBITDA due to leverage

  • Molycop cross-selling early-stage: 500-ton trial is proof-of-concept, not committed revenue; target 20,000–30,000 tons is aspirational

  • Equipment EBITDA negative Q1, flat margins Q2; margin recovery unproven despite order book

Street positioning

Tega's stock sits at ₹1,678.1, 27.94% below its all-time high and trading below its SMA20, SMA50, and SMA200—a meaningful drawdown that reflects the market's skepticism. The RSI of 41.1 signals neutral momentum, but volume is increasing, suggesting institutional attention. FII ownership rose 66 basis points QoQ to 2.80% (still cautious), while DII remains steady at 18.68%. The post-result price action has not held—the market did not reward the Molycop integration story, likely pricing in near-term execution risk on equipment recovery and the unresolved finance cost question. The discount to ATH is not an opportunity play; it's the market pricing in that equipment guidance cut and elevated leverage are real headwinds that won't resolve until H2 FY27 or later.

Risks, ranked by severity to a holder

How much each risk should concern a holder, and why

Equipment order book conversion failure

High

Guidance cut from 25% to 15% mid-year due to customer order delays. Equipment revenue dragging (H1 -5% YoY, +2% QoQ only). If H2 rebound doesn't materialize, FY27 guidance will miss and margins remain depressed.

Finance costs remain 10× prior guidance with vague relief timeline

High

₹4,086 Cr H1 (₹2,043 Cr per quarter) vs prior ₹110–120 Cr FY27 annual. Non-core asset monetization timeline is 12–18 months (vague). If delayed, debt reduction pushes into FY28 and adjusted margins stay under 11%.

Equipment EBITDA collapse Q1, flat Q2—margin recovery unproven

Medium

Q1 negative EBITDA, Q2 only +2% QoQ growth. Order book healthy but project-intensive nature suggests execution dependent. If margins don't recover to 20%+ historically, blended Tega-Molycop targets become at risk.

Molycop customer concentration: Grasberg at 67% throughput, Cobre Panamá permitting uncertain

Medium

Two customers represent meaningful upside (and downside) to Molycop revenue. Grasberg recovery to 80% by mid-2027 not guaranteed; Cobre Panamá contingent on mining permit. Downside could dampen Molycop volume growth below guidance.

Molycop cross-selling early-stage: 500-ton trial unproven at scale

Low

Synergy target USD 20M over 2–2.5 years. First cross-sell win is 500-ton grinding media trial with existing customer. Scaling to 20,000–30,000 tons is aspirational. If trials fail, synergy realization delays and margin expansion timeline extends.

What resolves the debate next quarter
  • 1 · Equipment order book conversion and H2 revenue ramp

    Management flagged 'strong rebound' expected in Q3 and Q4. Equipment H1 was only +2% QoQ; order book at ₹13,976 Cr should be convertible if customer approvals clear. This is the near-term make/break for the quarter-to-quarter narrative.

  • 2 · Non-core asset monetization and finance cost trajectory

    CFO Ravi Joshi said 12–18 month monetization window but no committed assets or timeline yet. Any concrete announcement of asset sales and paydown of ₹500 Cr+ of Molycop debt would validate the management narrative and ease the 10× finance cost overshoot.

  • 3 · Chile grinding facility commercial startup and consumables scaling

    Facility targeted for Jan 2027 commercial production. If on track and Tega successfully scales the 500-ton grinding media trial to 5,000+ tons in H2, that validates the synergy story and proves cross-selling is not just talk.

The number to track from here

Reported EBITDA margin of 14.2% is now the legacy KPI. Going forward, track two: (1) Equipment sequential revenue growth and margin expansion—if H2 doesn't see +10% QoQ revenue and margins north of 15%, the miss extends into FY28. (2) Adjusted PAT margin on a quarterly basis (ex-one-times, ex-Molycop integration costs). The path back to 11%+ adjusted margins (vs 10.6% in Q2) depends entirely on equipment recovery and leverage reduction. Molycop is performing; the company's near-term credibility hinges on equipment execution and finance cost relief.

Tega's acquisition of Molycop was the right move strategically—the combined platform has scale, synergy potential, and consumables growth on track. But it was also a leverage move: adjusted PAT margin dropped from legacy 11%+ (pre-acquisition) to 10.6% post-acquisition due to ₹4,086 Cr in finance costs. That gap is the story of the quarter, not the Molycop integration itself.

Near-term is a steady execution play, not a step-change. Equipment demand has to stabilize in H2 (order book is there; customers are delaying, not canceling). Finance costs have to normalize via non-core asset sales starting in H2. Long-term thesis—15% EBITDA margin, 15% consumables CAGR, USD 20M synergies—is intact but execution timeline extends. The stock's 27.94% discount to ATH is not a bargain; it's a fair repricing of the execution risk ahead. Hold for management to prove equipment recovery and asset sales. Upgrade only if H2 equipment revenue confirms and finance cost relief materializes.

Informational and educational content only. Not investment advice.